Achieve Life Sciences, Inc. (ACHV) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. While there are positive aspects such as the preparation for commercial launch and favorable safety outcomes, there are significant risks including regulatory approval, financial constraints, and competitive pressures. The Q&A section highlights uncertainties, particularly regarding the vaping study and funding, which could weigh on investor sentiment. Given the absence of immediate catalysts and the potential for delays, the overall stock reaction is likely to remain neutral.
Key Financial Performance
Cash, cash equivalents and marketable securities $48.1 million as of September 30, 2025.
Total operating expenses $14.7 million for the 3 months ended September 30, 2025, and $40.1 million for the 9 months ended September 30, 2025.
Net loss $14.4 million for the 3 months ended September 30, 2025, and $40 million for the 9 months ended September 30, 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Cytisinicline NDA submission and acceptance: Achieve Life Sciences has advanced significantly in its NDA submission and acceptance for cytisinicline as a treatment for nicotine dependence. The FDA has awarded a Commissioner's National Priority Voucher (CNPV) for the e-cigarette or vaping indication, expediting the NDA review timeline to 1-2 months instead of the standard 10-12 months.
Cytisinicline for COPD smokers: In Phase III trials, cytisinicline showed higher quit rates for smokers with COPD compared to placebo. This subgroup, often difficult to treat, demonstrated significant potential benefits from cytisinicline.
ORCA-OL long-term study: The ORCA-OL study showed favorable safety and tolerability for cytisinicline, with 97% of participants reporting it helped them quit or reduce nicotine use. The study also highlighted its potential efficacy and minimal side effects.
Addressable market for smoking cessation: The U.S. market includes nearly 29 million adult smokers, with over 15 million attempting to quit annually. Smoking-related costs exceed $600 billion annually, highlighting the significant market opportunity for cytisinicline.
Vaping cessation market: Cytisinicline could become the first FDA-approved treatment for vaping cessation, targeting 17 million adult e-cigarette users in the U.S., 60% of whom want to quit.
AI-driven commercialization strategy: Achieve is leveraging AI and machine learning for precision targeting, omnichannel marketing, and real-time performance monitoring. This approach aims to optimize resource allocation and improve revenue outcomes.
Team updates: Promotions and new hires include Dr. Mark Rubenstein as Interim Chief Medical Officer, Craig Donnelly as Chief Operations Officer, and Eric Atkinson as Chief Legal Officer, strengthening the team for regulatory and commercial milestones.
FDA Commissioner's National Priority Voucher (CNPV): The CNPV for vaping cessation accelerates the NDA review process, positioning cytisinicline as a potential first FDA-approved treatment for vaping dependence.
Commercial launch preparation: Achieve is preparing for a U.S. launch of cytisinicline in Q3 or Q4 2026, focusing on availability, access, and awareness through a data-driven approach.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Approval Risks: The company is awaiting FDA approval for cytisinicline with a PDUFA date set for June 20, 2026. Any delays or issues in the approval process could significantly impact the company's timeline and financial projections.
Market Access and Payer Challenges: Securing rapid, broad, and affordable coverage for cytisinicline is critical. Challenges in payer negotiations or reimbursement strategies could limit market penetration and revenue generation.
Supply Chain and Distribution Risks: The company is in the process of aligning its supply chain and commercial strategy. Any disruptions or inefficiencies in the supply chain could delay the product launch and affect availability.
Commercialization and Execution Risks: The success of the product launch depends on the effectiveness of the AI-driven commercialization strategy. Any failure in execution, targeting, or engagement could hinder market adoption.
Economic and Competitive Pressures: The smoking cessation market has not seen new FDA-approved treatments in nearly 20 years, but competitive pressures from existing treatments or new entrants could impact market share.
Clinical and Safety Risks: Although the ORCA-OL trial showed favorable safety outcomes, any unforeseen safety issues or adverse events could negatively impact regulatory approval and market acceptance.
Financial Risks: The company reported a net loss of $14.4 million for Q3 2025 and has a cash runway into the second half of 2026. Financial constraints could limit operational flexibility and strategic initiatives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
FDA Approval Timeline: The FDA has awarded Achieve a Commissioner's National Priority Voucher (CNPV) for the e-cigarette or vaping indication, expediting the NDA review timeline to 1-2 months instead of the standard 10-12 months. This could lead to a rapid approval and an earlier launch of cytisinicline by 8 months.
Launch Timeline: Cytisinicline is expected to launch in the third or fourth quarter of 2026, following the PDUFA action date of June 20, 2026.
Market Opportunity: Cytisinicline aims to address a significant unmet need in smoking cessation, targeting 29 million U.S. smokers and 17 million adult e-cigarette users, with 60% of the latter wanting to quit.
Vaping Cessation Indication: Achieve is preparing to initiate the ORCA-V2 Phase III trial for vaping cessation, with the CNPV enabling enhanced FDA engagement and a shortened NDA submission and approval timeline.
Commercial Strategy: Achieve is leveraging AI and machine learning for a data-driven commercialization strategy, focusing on precision targeting of healthcare professionals, patients, and payers to optimize campaigns and enhance engagement.
Regulatory Progress: The FDA has accepted the NDA for cytisinicline for smoking cessation, with a PDUFA action date set for June 20, 2026. The company has also completed its 120-day safety review and final site closeout visits for the ORCA-OL long-term exposure study.
Patient Feedback and Efficacy: Exit surveys from the ORCA-OL trial indicate that over 97% of participants believe cytisinicline helped them quit or reduce nicotine use, with many citing reduced cravings and minimal side effects as key benefits.
Pricing and Market Access: Achieve has completed payer segmentation and pricing research to guide engagement strategies and optimize reimbursement potential at launch. Proactive engagement with payers will begin in Q1 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Does the company have a retail strategy in addition to the specialty distributor?
A:Yes, there is a complementary retail strategy in place, but the specialty route is considered the quickest and optimal route initially.
Q:Does the cash runway into the second half of next year include funding for the vaping study?
A:No, additional capital will need to be raised to fund the vaping study.
Q:What is the protocol for the vaping study?
A:The protocol is similar to the smoking cessation trials: a 2-arm study with placebo and cytisinicline (3 mg, 3 times daily for 12 weeks) involving roughly 400 patients in each arm. The endpoint will be overall quit rates at the end of 12 weeks of treatment with a 24-week follow-up.
Q:How is the company planning to accelerate the Phase III vaping trial?
A:The company is exploring ways to streamline the clinical trial design by leveraging breakthrough designation and CNBV benefits. The trial will be a 12-week study with the same dosing as the smoking cessation trials.
Q:What are the benefits of cytisinicline for COPD patients?
A:Cytisinicline showed remarkable benefits for COPD smokers, who are highly nicotine-dependent. Quit rates for COPD smokers were similar to those without COPD, despite higher levels of dependence and depression. Cytisinicline can improve the efficacy of standard COPD treatments by helping patients quit smoking.
Q:What is the company's view on Pfizer reintroducing CHANTIX to the market?
A:The company believes cytisinicline has advantages over CHANTIX, including a superior side effect profile with significantly lower rates of nausea, vomiting, and other side effects. They see the smoking cessation market as large enough to accommodate both products.
Q:How does the company plan to manage the commercial infrastructure for smoking cessation and vaping products?
A:The vaping indication is expected to launch 12-14 months after the smoking cessation indication. The company will target different demographics: older, highly motivated quitters for smoking cessation and younger, digitally inclined vapers. Manufacturing will remain the same for both products.
Q:Review of Unclear Management Responses
A:Management avoided directly answering how they plan to accelerate the Phase III vaping trial beyond general statements about streamlining the design. Additionally, there was no specific detail on how they plan to fund the vaping study or the exact steps to address the manufacturing timeline for vaping.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI tool
Atkinson Chief
CNPV
COPD smoker
Chief Legal
Chief Officer
Commissioner National
Donnelly Chief
Dr Interim
FDA treatment
HCP
Head Medical
III trial
Interim Chief
Legal Officer
Medical Affairs
Phase III
activation
approach
audience message
campaign
cancer
care
career
chain
communication
cytisinicline review
death
dynamic
engagement
experience
indication
infrastructure
million
respondent
safety review
segmentation
specialty
vaping
ACHV Transcript
Achieve Life Sciences, Inc. (ACHV) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call summary and Q&A indicate a positive sentiment. The company's strategic plan shows strong product development with NDA approval and commercial launch goals. The Q&A reveals confidence in manufacturing and IP, though some details remain vague. The partnership with Adare Pharma Solutions and the AI-driven commercial platform are promising. Despite some uncertainties, the overall outlook is optimistic, with a potential market opportunity and supportive clinical data. The sentiment is positive, with a likely stock price increase in the short term.
Achieve Life Sciences, Inc. (ACHV) Q4 2025 Earnings Call Transcript
Unknown3-24
The earnings call reveals significant concerns: a net loss of $54.7 million, limited cash reserves, and ongoing economic and financial risks. The Q&A section highlights unproven commercial execution strategies and unclear timelines for manufacturing and regulatory approvals. While there is optimism for future product launches, the lack of finalized pricing strategies and potential supply chain issues further contribute to a negative outlook. These factors outweigh any positive aspects, suggesting a likely stock price decline in the short term.
Achieve Life Sciences, Inc. (ACHV) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call presents a mixed picture. While there are positive aspects such as the preparation for commercial launch and favorable safety outcomes, there are significant risks including regulatory approval, financial constraints, and competitive pressures. The Q&A section highlights uncertainties, particularly regarding the vaping study and funding, which could weigh on investor sentiment. Given the absence of immediate catalysts and the potential for delays, the overall stock reaction is likely to remain neutral.
Achieve Life Sciences, Inc. (ACHV) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call summary presents a mixed outlook. The company is on track with NDA submission and has positive clinical trial results, but faces financial challenges with a significant cash burn and net loss. The Q&A section reveals cautious optimism about pricing strategy and partnerships, but lacks clarity in some areas. The focus on cash management and the absence of priority review expectations temper the outlook. Overall, the sentiment is neutral, reflecting both potential positives and ongoing uncertainties.
ACHV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
